GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Mind Medicine
Shares of Mind Medicine, a biotech company researching psychedelics for the treatment of mental disorders, are a highly speculative bet. Their price is driven not by financial performance, but by clinical trial results and changes in legislation regarding these substances.
Share prices of companies in the market segment - Pharma psycho
Mind Medicine (MindMed) is a biotech company developing psychedelic-based drugs for the treatment of mental disorders. We've categorized it as a "Pharma: Psycho" company, and the chart below shows how investors view this new and controversial, yet potentially disruptive, segment of the pharmaceutical industry.
Broad Market Index - GURU.Markets
Mind Medicine (MindMed) is a biotech company developing psychedelic-based drugs for the treatment of mental disorders. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
MNMD - Daily change in the company's share price Mind Medicine
Shares of Mind Medicine, a company developing psychedelic-based therapies, are experiencing extreme volatility. Change_co measures the market's reaction to news about clinical trials and regulatory changes. This metric is an important component of formulas on System.GURU.Markets that evaluate speculative biotech companies.
Daily change in the price of a set of shares in a market segment - Pharma psycho
Mind Medicine (MindMed) Inc. is a biotech company focused on psychedelics. This chart highlights the sector's extreme volatility. A comparison with MNMD's performance helps assess it as a high-risk asset, dependent on clinical data and regulatory changes.
Daily change in the price of a broad market stock, index - GURU.Markets
Mind Medicine is one of the leading companies in the psychedelic medicine sector. This is a highly speculative and volatile sector. The chart below reflects average fluctuations in this niche, serving as an indicator of risks and investor expectations.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Mind Medicine
MindMed is a leading company developing psychedelic-based drugs. Its year-over-year performance reflects both progress in clinical trials and the evolving regulatory attitudes toward this new class of drugs.
Annual dynamics of market capitalization of the market segment - Pharma psycho
Mind Medicine (MindMed) Inc. is a biotech company developing psychedelic drugs for the treatment of mental disorders. Its stock price is entirely speculative and based on investor belief in the future legalization and medical potential of these substances, not on current financial performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
MindMed, a biotech company researching psychedelics, is one of the most speculative stories on the market. Its stock price is completely unrelated to the economy. Its price chart reflects the hopes, risks, and legislative changes surrounding one of the most controversial areas of medicine.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Mind Medicine
Lithium Americas, a company developing large lithium projects in Argentina and the United States, shows monthly fluctuations in the chart, reflecting lithium prices, as well as construction and permitting progress at its key projects, which are important to the battery supply chain.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
Mind Medicine (MindMed) Inc. is a biopharmaceutical company developing psychedelic-based drugs for the treatment of mental disorders. This sector is one of the most speculative in biotech. The chart below shows how investor interest and confidence in the entire psychedelic medicine industry has changed based on clinical trials and regulatory news.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mind Medicine is a leading company in the field of psychedelic medicine. Its shares are a bet on the future of LSD- and psilocybin-based drugs becoming legal. The move depends entirely on clinical data and regulatory changes, representing a high-risk play on a paradigm shift in psychiatry.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Mind Medicine
Mind Medicine is a company developing psychedelic-based drugs. Its weekly stock price is highly speculative and volatile, responding to regulatory changes, early-stage research results, and general sentiment in this niche sector.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
Mind Medicine is a company operating in the controversial field of psychedelic therapy. Comparing its weekly performance to the pharmaceutical sector is pointless. The chart shows how news about clinical trials and legalization are causing its shares to move at their own pace, separate from the industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Mind Medicine, a psychedelic therapy company, live in a world of their own. Their performance is driven by news about legalization and research. A chart comparing the stock to the S&P 500 clearly demonstrates how its stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
MNMD - Market capitalization of the company Mind Medicine
Mind Medicine's market capitalization chart is one of the most compelling stories in the psychedelic medicine sector. Its volatile dynamics reflect all the hopes and regulatory obstacles on the path to legalizing LSD-based drugs and other substances for the treatment of mental disorders. It's a visual representation of a risky bet on a new paradigm in psychiatry.
MNMD - Share of the company's market capitalization Mind Medicine within the market segment - Pharma psycho
Mind Medicine (MindMed) is a leading company developing psychedelic-based drugs for the treatment of mental disorders such as anxiety and addiction. Its market share reflects its pioneering status and investor confidence in this new wave of therapeutics. The chart below provides a barometer of expectations for the psychiatric revolution.
Market capitalization of the market segment - Pharma psycho
Mind Medicine (MindMed) is a leading company developing psychedelic-based drugs for the treatment of mental disorders. The chart below shows the overall market capitalization of the psychopharmaceutical sector. Its dynamics reflect both scientific progress and the regulatory barriers to the legalization of these new therapies.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph shows an attempt to transform psychedelics into drugs. Mind Medicine is developing therapies based on LSD and other substances to treat mental disorders. Its extremely volatile trendline reflects both the enormous potential and the regulatory and social barriers to this revolution.
Book value capitalization of the company, segment and market as a whole
MNMD - Book value capitalization of the company Mind Medicine
Mind Medicine's book value is its financial reserves and intellectual property portfolio for psychedelic drugs used to treat mental disorders. This represents the scientific capital needed to conduct groundbreaking research. The chart shows how the company manages its "budget" for long and costly clinical trials.
MNMD - Share of the company's book capitalization Mind Medicine within the market segment - Pharma psycho
Mind Medicine is a biotech company developing psychedelic-based drugs. Its assets include intellectual property and clinical trial data. The chart shows a minimal share of physical assets, which is typical for an R&D company operating at the cutting edge of science.
Market segment balance sheet capitalization - Pharma psycho
Developing psychedelic therapies like Mind Medicine's is a science-intensive, not capital-intensive, business. Its value lies in patents and clinical trial results. Compared to the pharmaceutical sector's assets, the company's model appears very "lightweight" at the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Mind Medicine's book value is not its product lines, but rather its intellectual property portfolio and capital for conducting clinical trials of psychedelic-based drugs for the treatment of addictions and mental disorders. These assets reflect the financial resources available for working in this emerging field of medicine. The chart illustrates the scale of this company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Mind Medicine
Mind Medicine, a company developing psychedelic-based drugs, is valued by the market solely on expectations. Its market price to book value (its cash) ratio is a clear indicator of investors' faith in the future legalization and medical use of these substances.
Market to book capitalization ratio in a market segment - Pharma psycho
Mind Medicine is a company developing psychedelic drugs for the treatment of mental disorders. This is a highly speculative field. Its market valuation on this chart reflects investors' pure faith that psychedelics will become mainstream in medicine.
Market to book capitalization ratio for the market as a whole
Mind Medicine (MindMed) is a leading company developing psychedelic-based drugs for the treatment of mental disorders. Its market capitalization is a bet on the legalization and medical use of these substances. This metric demonstrates how valuations in such pioneering industries depend on future regulatory changes and shifts in public opinion.
Debts of the company, segment and market as a whole
MNMD - Company debts Mind Medicine
Mind Medicine (MindMed) is a biotech company at the forefront of psychedelic research for the treatment of mental disorders. Its entire operations are financed through raised capital, including debt. This chart reflects the massive investment required to conduct clinical trials and validate this entirely new class of drugs.
Market segment debts - Pharma psycho
Mind Medicine (MindMed) is a biotech company pioneering the development of psychedelic-based drugs (such as LSD and psilocybin) for the treatment of mental disorders. This is a high-risk and innovative field. The chart shows how the company is funding its expensive clinical trials by raising capital from investors who believe in the potential of this new class of therapy.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Mind Medicine
Mind Medicine (MindMed) is a company developing psychedelic-based drugs for the treatment of mental disorders and addictions. This is a cutting-edge but high-risk field with lengthy and expensive clinical trials. This chart shows how much the company relies on debt to finance its research toward potential legalization and commercialization.
Market segment debt to market segment book capitalization - Pharma psycho
Mind Medicine (MindMed) is a biotech company developing psychedelic drugs for the treatment of mental disorders. This is a new and risky field. This chart shows how the company is funding its unique clinical research, relating its debt structure to the broader picture of the capital-intensive biotech sector.
Debt to book value of all companies in the market
Mind Medicine (MindMed) Inc. is a company developing psychedelic-based drugs for the treatment of mental disorders. This is a cutting-edge but high-risk field, requiring long-term investment in research. How heavily is the company reliant on debt? This chart of total market debt helps assess the riskiness of its financial strategy.
P/E of the company, segment and market as a whole
P/E - Mind Medicine
Mind Medicine (MindMed) is a biopharmaceutical company developing psychedelic-based drugs for the treatment of mental disorders. This chart reflects the high speculative interest in this emerging field of medicine. The valuation is highly volatile and depends on research results and regulatory changes.
P/E of the market segment - Pharma psycho
Mind Medicine (MindMed) is a biotech company developing drugs based on psychedelics, such as LSD and psilocybin, to treat mental disorders. This chart shows the average valuation for psychopharmaceuticals, giving investors context for evaluating this innovative but high-risk field of medicine.
P/E of the market as a whole
Mind Medicine (MindMed) is a leading company in the psychedelic medicine sector, developing drugs for the treatment of mental disorders. The company's valuation is a bet on the future legalization and medical acceptance of these substances. How much does it depend on these unique factors, and how much on the general investor appetite for high-risk biotech?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Mind Medicine
Mind Medicine (MindMed) is a biotech company developing psychedelic-based drugs for the treatment of mental disorders and addictions. This chart reflects investor confidence in the revolutionary potential of this new class of therapy. Future profits are entirely dependent on clinical trial results and regulatory changes.
%20P%2FE%20Mind%20Medicine&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Mind-Medicine&v=1772513730325 "Chart of the company's future (projected) P/E Mind Medicine")
Future (projected) P/E of the market segment - Pharma psycho
Mind Medicine (MindMed) Inc. is a biotech company developing psychedelic-based drugs (LSD, psilocybin) for the treatment of mental disorders and addictions. This is a cutting-edge but risky field. The chart shows expectations for the psychopharmacology sector. This allows investors to compare their confidence in MindMed's development pipeline with those of their competitors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772513730330 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
Mind Medicine (MindMed) Inc. is one of the most prominent companies in the psychedelic medicine sector. It develops drugs based on LSD and other substances for the treatment of mental disorders. The company is valued at pure expectations. This chart shows how ready the market is for such a revolutionary, yet highly controversial and risky, investment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513730334 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Mind Medicine
Mind Medicine (MindMed) is a company developing psychedelic-based drugs for the treatment of mental disorders. At the forefront of a controversial but promising field, its financial results reflect investments in clinical research. The chart shows the capital burned to potentially create a new class of drugs.
Profit of companies in the market segment - Pharma psycho
Mind Medicine (MindMed) is a biotech company conducting research into psychedelic drugs for the treatment of mental disorders and addictions. This chart, which reflects the profitability of the pharmaceutical sector, is important as an indicator of the market's readiness for innovation. MindMed's success depends on regulatory changes and the results of clinical trials of their innovative approaches.
Overall market profit
Mind Medicine (MindMed) Inc. is a leading company developing psychedelic-based drugs for the treatment of mental disorders. This is a high-risk and innovative field. The overall growth in corporate profits, reflected in this chart, creates excess capital in the economy and increases investor risk appetite, making it easier for MindMed to raise funds for research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Mind Medicine
Mind Medicine (MindMed) is a biotech company developing psychedelic-based drugs for the treatment of mental disorders such as anxiety and addiction. Its future depends on clinical trials and regulatory changes. This chart reflects analysts' speculative expectations regarding a potential breakthrough in psychiatry.
%20profit%20of%20the%20company%20Mind%20Medicine&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Mind-Medicine&v=1772513730371 "Graph of future (projected) profit of the company Mind Medicine")
Future (predicted) profit of companies in the market segment - Pharma psycho
Mind Medicine (MindMed) Inc. is a biotech company developing psychedelic-based drugs for the treatment of mental disorders. Its future depends on the success of clinical trials and changes in the regulatory environment. This chart for the biotech sector shows the overall risk appetite of investors and their belief in the potential of breakthrough, yet unproven, therapeutic approaches.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772513730376 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
Mind Medicine, a company developing psychedelic therapies, is working at the cutting edge of science. Its future depends on clinical success and regulatory approval. However, overall economic expectations, as shown in the chart, are influencing investor willingness to invest in such innovative and high-risk fields.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513730384 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Mind Medicine
Mind Medicine (MindMed) Inc. is a biotech company developing psychedelic-based drugs for the treatment of mental disorders. Because the industry is new and revenue is nonexistent, this chart is key. It shows investors' speculative estimates of the company's huge potential market and future sales if its drugs are approved.
P/S market segment - Pharma psycho
Mind Medicine (MindMed) Inc. is a biotech company developing psychedelic-based medications for the treatment of mental disorders. Its valuation is based on the future potential of these innovative therapies. This chart reflects the average valuation in the sector, allowing one to understand how investor expectations for MindMed's developments compare to overall interest in this emerging field.
P/S of the market as a whole
Mind Medicine (MindMed) is a biotech company developing psychedelic-based drugs for the treatment of mental disorders and addictions. This chart, which reflects revenue estimates for companies with actual sales, highlights that MindMed's valuation is a bet on a future revolution in psychiatry and the legalization of new treatments, rather than on current cash flows.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Mind Medicine
Mind Medicine (MindMed) is a biotech company developing psychedelic-based drugs for the treatment of mental disorders and addictions. Its valuation is a bet on a medical revolution. This metric reflects investor expectations for the future legalization and commercialization of such therapies, which could open a huge market.
%20P%2FS%20Mind%20Medicine&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Mind-Medicine&v=1772513730390 "The graph of the company's future (projected) P/S Mind Medicine")
Future (projected) P/S of the market segment - Pharma psycho
Mind Medicine (MindMed) Inc. is a biotech company developing psychedelic-based medications for the treatment of mental illnesses such as anxiety and addiction. This chart shows average revenue expectations for the innovative pharmaceutical sector. It allows one to assess how highly the market perceives MindMed's potential in this emerging field.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772513730391 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
Mind Medicine (MindMed) is a biotech company developing psychedelic-based drugs for the treatment of mental disorders and addictions. This chart reflects overall investor sentiment. MindMed is at the forefront of a potential revolution in psychiatry, and its research advances could fundamentally change treatment approaches and create a new market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513730393 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Mind Medicine
This chart illustrates the revenue of Mind Medicine (MindMed) Inc., a biopharmaceutical company developing psychedelic-based drugs for the treatment of mental disorders. During clinical trials, its revenue may be zero or consist of affiliate fees, reflecting progress in scientific development rather than commercial sales.
Sales of companies in the market segment - Pharma psycho
Mind Medicine (MindMed) Inc. is a biotechnology company developing psychedelic-based drugs for the treatment of mental disorders. This chart shows the emerging market for psychedelic medicine. MindMed is a pioneer in this field, and its clinical trials have the potential to legalize and commercialize an entirely new class of drugs.
Overall market sales
Mind Medicine is a biotech company researching psychedelic drugs for the treatment of mental disorders. Its future depends on successful trials and regulatory changes. The overall economic situation, shown in this chart, influences investor willingness to fund such cutting-edge and risky ventures.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Mind Medicine
Mind Medicine (MindMed) is a biotech company researching psychedelics for the treatment of mental disorders. Its revenue forecast is based on expectations of clinical trial success. The chart reflects analysts' confidence in the legalization and commercialization of this new class of drugs.
%20sales%20of%20the%20company%20Mind%20Medicine&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Mind-Medicine&v=1772513730412 "Schedule of future (projected) sales of the company Mind Medicine")
Future (projected) sales of companies in the market segment - Pharma psycho
Mind Medicine (MindMed) is a leading company developing psychedelic-based medications for the treatment of mental disorders and addictions. The company is at the forefront of a revolution in psychiatry. This chart shows the forecast for the entire psychopharmacology market, where MindMed's drugs have the potential to create an entirely new category of therapy.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772513730413 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
Mind Medicine (MindMed) Inc. is a company developing psychedelic drugs for the treatment of mental disorders. It is at the forefront of medical innovation, and its success depends on regulatory changes and research results. This chart shows the overall investment climate, but for MindMed, regulatory sentiment and public acceptance of new therapies are more important.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513730414 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Mind Medicine
Mind Medicine (MindMed) is a biotech company researching psychedelics such as LSD and psilocybin for the treatment of mental disorders. Being in the clinical stage, it incurs significant research expenses. This chart shows its net losses—investments in potentially revolutionary treatments that could transform psychiatry.
Market segment marginality - Pharma psycho
#VALUE!
Market marginality as a whole
Mind Medicine (MindMed) is a biotech company developing psychedelic-based drugs for the treatment of mental disorders such as anxiety and addiction. This chart, reflecting the current economic climate, is just the backdrop for them. MindMed is betting on a future revolution in psychiatry, and their success depends on clinical data and regulatory approvals.
Employees in the company, segment and market as a whole
Number of employees in the company Mind Medicine
Mind Medicine (MindMed) is a biotech company developing psychedelic-based drugs. It operates with a small team of drug development experts, outsourcing many functions. This chart illustrates a typical development-stage biotech model, focused on clinical trial management.
Share of the company's employees Mind Medicine within the market segment - Pharma psycho
Mind Medicine (MindMed) is a biotech company developing psychedelic-based medications for the treatment of mental illnesses. This chart shows the percentage of scientists and researchers the company is attracting in this innovative field of medicine. This increase indicates the expansion of its clinical programs and its commitment to becoming a leader in this promising segment.
Number of employees in the market segment - Pharma psycho
Mind Medicine (MindMed) Inc. is a biotech company developing psychedelic-based medications for the treatment of mental illnesses. This chart reflects employment trends in the innovative psychedelic pharmaceutical sector. The growing number of researchers and clinicians in this field signals growing scientific and investment interest in this new class of therapeutic drugs.
Number of employees in the market as a whole
Mind Medicine (MindMed) is a biotech company researching psychedelic compounds for the treatment of mental disorders such as anxiety and addiction. The company is at the forefront of a resurgence of interest in this field of medicine. This chart shows how innovative approaches in pharmaceuticals can create new niches and jobs for scientists and doctors.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Mind Medicine (MNMD)
Mind Medicine (MindMed) is a biotech company developing psychedelic-based drugs. This chart is a prime example of intellectual capital valuation. The company's value is based solely on its research potential and development pipeline. The chart shows how highly the market values the future value of these innovative treatments per scientist.
%20of%20the%20company%20Mind%20Medicine%20(MNMD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Mind-Medicine-MNMD&v=1772513730433 "Chart of market capitalization per employee (in thousands of dollars) of the company Mind Medicine (MNMD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
Mind Medicine is a biotech company developing psychedelic-based drugs for the treatment of mental disorders. Its valuation is based on the potential of its research and the potential to transform treatment approaches. This chart demonstrates the high valuation of its intellectual capital and future prospects based on its small staff of scientists.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772513730434 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
Mind Medicine (MindMed) is a biotech company developing psychedelic-based drugs for the treatment of mental disorders and addictions. The chart reflects the high scientific potential of this emerging field of medicine. The company's entire value is based on the hope for future drugs created by its team of scientists.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513730436 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Mind Medicine (MNMD)
Mind Medicine (MindMed) is a biotech company developing psychedelic-based drugs (such as LSD and MDMA) for the treatment of mental disorders. This is early-stage R&D. This chart shows the company's capital burn rate: the amount of capital the company spends on each scientist and physician during expensive clinical trials.
%20Chart%20Mind%20Medicine%20(MNMD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Mind-Medicine-MNMD&v=1772513730438 "Company Profit Per Employee (in thousands of dollars) Chart Mind Medicine (MNMD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
Mind Medicine (MNMD) is a biopharmaceutical company developing psychedelics (LSD, MDMA) for the treatment of mental disorders. It is a clinical-stage R&D company. This metric (loss per employee) reflects the high cost of conducting clinical trials in this complex and new field.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772513730439 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
Mind Medicine (MNMD) is a clinical-stage biotech company specializing in the development of psychedelics (LSD, MDMA) for the treatment of mental disorders. Like GHRS, the company is unprofitable. This chart shows the company's capital burn rate: the operating loss per research team developing the new drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513730440 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Mind Medicine (MNMD)
Mind Medicine is a biotech company developing psychedelic-based drugs for the treatment of mental disorders and addictions. This chart reflects the initial stages of monetizing its research. Revenue at this stage likely comes from partnerships, and its growth per employee is an indicator of interest in its scientific research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Mind-Medicine-MNMD&v=1772513730441 "Sales chart per company employee Mind Medicine (MNMD)")
Sales per employee in the market segment - Pharma psycho
Mind Medicine (MindMed) is a leading company in the psychedelic medicine sector, developing drugs based on LSD and other compounds. This chart shows how productive their R&D team is. It measures revenue (likely from partnerships) per scientist, comparing it to other companies in this emerging segment.
Sales per employee for the market as a whole
Mind Medicine (MNMD) is a biotech company developing psychedelic-based drugs (LSD, MDMA) for the treatment of mental disorders. The company is in the clinical stage and has no commercial revenue. This chart illustrates a typical situation for an R&D company: its entire staff of scientists and doctors is focused on conducting research, generating data rather than revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Mind Medicine (MNMD)
Mind Medicine is another biotech company developing psychedelic-based drugs (LSD, MDMA) for the treatment of mental disorders. This chart shows strong bearish interest. As with GHRS, investors are betting against this speculative industry, anticipating regulatory hurdles or clinical trial failure.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Mind-Medicine-MNMD&v=1772513730443 "Short Shares Chart for the Company Mind Medicine (MNMD)")
Shares shorted by market segment - Pharma psycho
Mind Medicine (MindMed) is a biotech company developing psychedelic-based drugs (LSD, MDMA) for the treatment of mental disorders. This chart shows bearish sentiment. "Shorts" here are betting that their clinical trials will fail or that regulators (FDA, DEA) will block them.
Shares shorted by the overall market
Mind Medicine is researching psychedelics for the treatment of mental disorders. It's one of the most speculative and hyped sectors of biotech. When this graph, which measures general fear, climbs, investors are quick to dump these "lottery tickets." For MNMD, surviving this storm is a top priority.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Mind Medicine (MNMD)
Mind Medicine is a biotech company developing psychedelics for the treatment of mental disorders. The stock is highly speculative. This chart can soar above 70 on positive R&D news or hype. The <30 zone often reflects setbacks, regulatory barriers, or risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Mind-Medicine-MNMD&v=1772513730458 "RSI 14 indicator chart for the company's stock Mind Medicine (MNMD)")
RSI 14 Market Segment - Pharma psycho
MindMed (MNMD) is a pioneer in psychedelics. They develop (LSD, MDMA) for the treatment of mental disorders (anxiety, ADHD). RSI_14_Seg for "Pharma psycho" (biotech) shows the overall sentiment. The chart helps us understand: is MNMD's volatility just hype or is the entire sector overheated?
RSI 14 for the overall market
Mind Medicine (MNMD) is pure speculation on the "future." This chart is its lifeline. During periods of market euphoria, investors are willing to fund the "dream" of psychedelics. In moments of panic, capital flees unprofitable R&D projects, and MNMD risks running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MNMD (Mind Medicine)
Mind Medicine (MNMD) is a biotech company developing psychedelic-based drugs (LSD, MDMA) for the treatment of mental disorders such as anxiety and ADHD. This chart reflects analyst consensus. Their price targets are speculative and based on clinical trial data and potential regulatory changes.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MNMD-Mind-Medicine&v=1772513730472 "A chart showing analyst consensus forecasts for the expected stock price. MNMD (Mind Medicine)")
The difference between the consensus estimate and the actual stock price MNMD (Mind Medicine)
Mind Medicine (MNMD) is one of the most prominent companies in the psychedelics sector, developing drugs based on LSD and other compounds for the treatment of anxiety and ADHD. This chart is an R&D barometer. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their clinical programs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MNMD-Mind-Medicine&v=1772513730474 "A chart showing the difference between the consensus forecast and the actual stock price. MNMD (Mind Medicine)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
Mind Medicine (MNMD) is a leading company in the field of psychedelic medicine. It develops LSD and MDMA derivatives for the treatment of anxiety disorders and addictions. This chart shows general expectations for the psychopharma sector, reflecting whether experts believe in the medical potential of these controlled substances.
Analysts' consensus forecast for the overall market share price
Mind Medicine (MNMD) is a leading company in the psychedelic medicine sector. They are conducting clinical trials of LSD-based drugs and other compounds for the treatment of anxiety and addiction. This chart shows the overall risk appetite. It reflects the market's willingness to fund breakthrough, yet regulatoryly complex and speculative, areas of medicine.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Mind Medicine
Mind Medicine (MindMed) is one of the most well-known companies in the psychedelic medicine field. They are conducting clinical trials of LSD and MDMA-based drugs for the treatment of anxiety and addiction. This chart represents pure R&D activity. It likely reflects the market's confidence in their clinical data, their cash runway, and the regulatory climate for these controversial substances.
AKIMA Market Segment Index - Pharma psycho
Mind Medicine (MNMD) is a biotech leader in the psychedelic revolution (like Atai); the company is developing a portfolio of drugs (LSD, MDMA) for the treatment of severe mental disorders. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this futuristic (and risky) model (MNMD) differentiate it from the average pharma company?
The AKIM Index for the overall market
Mind Medicine is a biotech company developing psychedelic drugs (LSD, MDMA) for the treatment of mental disorders (anxiety, depression). This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding such bold and speculative scientific bets.
